XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2022
Xbrane has released the company's 2022 Annual and Sustainability Report. The report summarises business, financial performance and work on sustainability.
“ We are proud of our collaboration with STADA and to have taken Ximluci®, devloped under the name Xlucane™, from cell line development to approval and manufacturing, via our patented platform
technology” says Martin Åmark CEO.
Xbrane Biopharma AB’s annual report for 2022 is now available at the company’s website, www.xbrane.com.
The annual report includes the corporate governance report and the sustainability report for 2022.
The Report is distributed to the shareholders and others that made such request. It can also be ordered from Xbrane Biopharma on the following address:
Xbrane Biopharma AB
Retzius väg 8
171 65 Solna
Or via e-mail: firstname.lastname@example.org
Martin Åmark, CEO
M: +46 76 309 37 77
Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and is launched during the first quarter 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com